Double blind randomized, controlled phase I dose escalation trial to evaluate the safety and immunogenicity of the WRAIR AMA1 malaria antigen (FMP2.1) adjuvanted in GSK's AS02A vs. rabies vaccine in malaria-experienced adults in Bandiagara, Mali.

Trial Profile

Double blind randomized, controlled phase I dose escalation trial to evaluate the safety and immunogenicity of the WRAIR AMA1 malaria antigen (FMP2.1) adjuvanted in GSK's AS02A vs. rabies vaccine in malaria-experienced adults in Bandiagara, Mali.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Malaria vaccine (Primary) ; AS02; Rabies vaccine
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 19 Jun 2012 Additional lead trial centres, drug company and location added as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Actual end date changed from 1 Dec 2005 to 1 Dec 2006 as reported by ClinicalTrials.gov.
    • 15 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top